Advantages:

To describe the effect of intravitreal ranibizumab for the treatment of choroidal neovascularisation and macular edema secondary to Best’s vitelliform macular dystrophy.

Methods:

A 38-year-old Asian woman with confirmed Best’s disease presented with decreased visual acuity (VA) due to secondary choroidal neovascularisation and macular edema. She was treated with a single intravitreal injection of ranibizumab (Lucentis, 0.5 mg).

Effectiveness / Safety:

Best-corrected VA recovered from 0.2 preoperatively to 0.6 over a period of 1 year. Optical coherence tomography (OCT) demonstrated regression of the CNV, resolution of the macular edema and regression of vitelliform material.

Take home message:

A single intravitreal injection of ranibizumab may be safe and effective treatment to make functional improvement and to keep the retinal architecture in a Asian woman suffering from Best’s vitelliform macular dystrophy.